Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.47 |
| ▸ | CDK7 | P50613 | 10/20 | 0.46 |
| ▸ | CDK9 | P50750 | 10/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | ROS1 | P08922 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013968 | 0.78 | CDK1 (0.37) | CDK2CDK5 | |
| SCHEMBL3959009 | 0.77 | ALK (0.51) | ALKCDK7CDK9METROS1 | |
| SCHEMBL375643 | 0.76 | ALK (0.67) | ALKCDK7CDK9METROS1 | |
| SCHEMBL29666260 | 0.76 | ALK (0.67) | ALKCDK7CDK9METROS1 | |
| SCHEMBL1491777 | 0.75 | CDK7 (0.60) | ALKCDK7CDK9METROS1 | |
| SCHEMBL3959979 | 0.75 | CDK7 (0.50) | ALKCDK7CDK9METROS1 | |
| SCHEMBL2825488 | 0.75 | ALK (0.49) | ALKCDK7CDK9METROS1 | |
| SCHEMBL31471890 | 0.75 | ALK (0.49) | ALKCDK7CDK9METROS1 | |
| SCHEMBL29015705 | 0.74 | YTHDC1 (0.33) | ALK | |
| SCHEMBL30424513 | 0.74 | YTHDC1 (0.33) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271630-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-8592432-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ROS1, INSR, IGF1R | ALK 6/4885CDK7 449/4885CDK9 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.